NATIONAL-TSING-HUA-UNIV
4.3.2020 10:02:08 CET | Business Wire | Press release
Although unmanned aerial vehicles (UAV) are commonly used in the fields such as communications and agriculture, their use is hampered by their small size and limited battery capacity. However, a multi-disciplinary team at National Tsing Hua University led by professors Tang Kea-tiong of the Department of Electrical Engineering and Lo Chung-chuan of the Department of Life Sciences has recently developed an artificial intelligence (AI) chip that mimics the optical nerves of the fruit fly, allowing drones to automatically avoid obstacles while remaining in an ultra-power-saving mode.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005029/en/
Most of the UAVs currently in use rely on the transmission and reflection of electromagnetic waves to detect and avoid obstacles, but this consumes a lot of power. An alternative approach to avoiding obstacles is to use optical lenses to capture and analyze images, but the amount of information to be processed is too large to be done quickly, and this approach also consumes much power.
Intrigued by the fruit fly’s uncanny ability to avoid obstacles, Tang figured that it might be possible to replicate the optical nerve of this tiny insect and adapt it to AI applications.
The first task was to solve the problem of information overload. According to Tang, the image sensor currently used in cameras and mobile phones have millions of pixels, whereas the eye of a fruit fly has only about 800 pixels. When the fruit fly’s brain processes such visual signals as contour and contrast, it utilizes a kind of detection mechanism which automatically filters out unimportant information, and only pays attention to moving objects liable to collide with.
By imitating this detection mechanism, the research team has developed an AI chip which makes it possible to use hand gestures and an image sensor to operate a drone.
First the drone is taught to focus on what’s most important, and then it’s taught how to judge distance and the likelihood of a collision. For this purpose, Lo conducted a detailed investigation on how the fruit fly detects optical flow, for which purpose he made extensive use of the maps of the fruit fly’s neural pathways produced by the Brain Research Center at NTHU. “Optical flow is the relative trajectory left in the field of vision by nearby moving objects, and which is used by the brain to determine its distance and to avoid obstacles,” Lo explained.
Tang said that the AI chip developed by his research team represents a major breakthrough in the area of in-memory computing. Computers and mobile phones first move data from the memory to the CPU’s central processing unit, and once it’s processed, the data is moved back to the memory for storage, and such a process is what consumes up to 90% of the energy and time of the AI deep-learning process. By contrast, the AI chip developed by the NTHU team mimics neuronal synapses, allowing it to perform computations in the memory, which greatly improves efficiency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005029/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
